BENTLEY-SYSTEMS
7.4.2022 22:03:11 CEST | Business Wire | Press release
Bentley Systems, Incorporated (Nasdaq: BSY), the infrastructure engineering software company, today announced it has acquired Watertown, Massachusetts-based ADINA R & D Inc., a leading developer of finite element analysis software applications used in a comprehensively diverse range of engineering fields (adina.com ). ADINA was founded in 1986 by Dr. Klaus-Jürgen Bathe, professor of mechanical engineering at the Massachusetts Institute of Technology and a world-renowned leader in the field of finite element analysis and its applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220406006024/en/
Civil, structural, and mechanical engineers choose ADINA software for its authoritative veracity, including in analysis of buildings, bridges, stadiums, pressure vessels, dams, and tunnels. By virtue of the ADINA System’s integral robustness across disciplines, materials, and simulation domains (structures, mechanical, fluids, thermal, electromagnetic, and multi-physics), engineers use it to perform comprehensive safety and performance studies where reliability and resilience are of critical importance.
With infrastructure digital twins, users can simulate the complete behavior of structures to create confidence in designs that are much safer and more cost-effective than those merely analyzed to meet prescribed code standards. Of particular importance for infrastructure resilience, ADINA will also be applied within digital twins of existing infrastructure assets, now made practical by the Bentley iTwin platform, to simulate their responses and vulnerabilities to stresses so extreme that nonlinear effects must be considered—caused (for instance) by seismic, wind, flood, pressure, thermal, collision, or blast forces.
The ADINA System’s nonlinear simulation capabilities will in turn become directly accessible, through convenient technical and commercial integration, to users of Bentley Systems’ uniquely comprehensive modeling and simulation software portfolio for infrastructure engineering. As the ADINA System’s nonlinear extensions are introduced to complement these existing physical simulation applications—currently spanning STAAD, RAM, SACS, MOSES, AutoPIPE, PLAXIS, LEAP, RM, LARS, SPIDA, and PLS—the scope of mainstream simulation underlying the engineering of infrastructure resilience will be valuably enhanced. ADINA’s advantages also include advanced dynamics, 3D solid FEM, buckling, substructuring, and advanced meshing for critical joints and sections.
“Incorporating ADINA and its creators is very exciting for all of our engineering simulation teams, as it will also be for existing and new users,” said Raoul Karp, vice president, engineering simulation at Bentley Systems. “Dr. Bathe literally wrote the book on advancing finite element simulations, and the ADINA System provides the reference for benchmarking all other disparate analysis approaches. We will now be able to extend nonlinear realism across all of our infrastructure digital twin simulation offerings.”
Founder of ADINA Dr. K.J. Bathe, who will remain as a technical advisor, said, “My colleagues and I are proud to be joining Bentley Systems’ broad and deep simulation team. Our aim in the development of ADINA has always been to provide a most reliable and efficient analysis tool to scientists and engineers, and it is wonderful that with Bentley, ADINA will now be used and further developed with great potential for solving the varied and interrelated challenges of infrastructure resilience.”
Image 1
:
Caption: The frictional sliding of a prestressed concrete bridge girder can be studied with ADINA technology.
Image 2
:
Caption: Collapse analysis of pressurized pipe can be performed with ADINA software.
Image 3
:
Caption: Simulation of a pipe break in a nuclear reactor using ADINA technology.
Image 4
:
Caption: Sloshing of an oil tank with the base subjected to horizontal ground motion with ADINA software.
##
About Bentley Systems
Bentley Systems (Nasdaq: BSY) is the infrastructure engineering software
company. We provide innovative software to advance the world’s infrastructure – sustaining both the global economy and environment. Our industry-leading software solutions are used by professionals, and organizations of every size, for the design, construction, and operations of roads and bridges, rail and transit, water and wastewater, public works and utilities, buildings and campuses, mining, and industrial facilities. Our offerings include MicroStation
-based applications for modeling and simulation, ProjectWise
for project delivery, AssetWise
for asset and network performance, Seequent’s leading geoprofessional software portfolio, and the iTwin
platform for infrastructure digital twins. Bentley Systems employs more than 4,500 colleagues and generates annual revenues of approximately $1 billion in 186 countries.
www.bentley.com
© 2022 Bentley Systems, Incorporated. Bentley, the Bentley logo, ADINA, AssetWise, AutoPIPE, iTwin, LARS, LEAP, SPIDA, MicroStation, MOSES, PLAXIS, PLS, ProjectWise, RAM, RM, SACS, Seequent, and STAAD are either registered or unregistered trademarks or service marks of Bentley Systems, Incorporated or one of its direct or indirect wholly owned subsidiaries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220406006024/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
